<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539110</url>
  </required_header>
  <id_info>
    <org_study_id>09-04-07-01</org_study_id>
    <nct_id>NCT00539110</nct_id>
  </id_info>
  <brief_title>Differential Effects of Zolpidem Versus Ramelteon in Burned Children</brief_title>
  <acronym>Sleep3</acronym>
  <official_title>Differential Effects of Zolpidem Versus Ramelteon on Nocturnal Sleep in Pediatric Burn Patients: A Prospective, Randomized Crossover Trial With Polysomnographic Recordings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine sleep changes following therapeutic drug interventions designed to promote sleep.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Polysomnography Data</measure>
    <time_frame>2 weeks postburn</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine if intervention product elicits more total sleep time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>2 weeks postburn</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>evaluate the PK of zolpidem following standard dosing practices</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sleep</condition>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medication dosed at 2200 and 0200 per feeding tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ramelteon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dosed at 2200 and 0200 per the feeding tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolipidem</intervention_name>
    <description>dosed at 2200 and 0200 per feeding tube</description>
    <arm_group_label>zolpidem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramelteon</intervention_name>
    <description>medication dosed at 2200 and 0200 per feeding tube</description>
    <arm_group_label>ramelteon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn injury &gt; 20% total body surface area

          -  Between 3 and 18 years of age

          -  &lt; 7 days from acute injury

          -  Written informed consent and HIPPA release signed

        Exclusion Criteria:

          -  Suspected anoxic brain injury or head injury

          -  Hepatic or endocrine disease

          -  History of alcoholism or substance abuse

          -  Pre-existing neurological or primary psychiatric disorder

          -  Medical history of pre-existing sleep disorder or lactose deficiency

          -  Questionable survival (&lt;72 hrs) as decided by PI

          -  Receipt of drugs with known effects on sleep within 24 hrs of study entry

          -  No informed consent/HIPPA release
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele M Gottschlich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospital for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 13, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2007</firstreceived_date>
  <firstreceived_results_date>May 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shriners Hospitals for Children</investigator_affiliation>
    <investigator_full_name>Michele Gottschlich</investigator_full_name>
    <investigator_title>Director, Nutrition Services</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zolpidem First, Then Ramelteon</title>
          <description>medication dosed at 2200 and 0200 per feeding tube
washout with no sleep meds (3 nights); zolpidem (x4 nights); washout (x3 nights); then ramelteon (x4 nights)</description>
        </group>
        <group group_id="P2">
          <title>Ramelteon, Then Zolpidem</title>
          <description>medication dosed at 2200 and 0200 per the feeding tube
washout with no sleep meds (x3 nights); ramelteon (x4 nights); washout (x3 nights); then zolpidem (x 4 nights)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were ten patients total, crossover design, so each of the 10 patients received both zolpidem and ramelteon.
Mean age 7.8 years</population>
      <group_list>
        <group group_id="B1">
          <title>Zolpidem First, Then Ramelteon</title>
          <description>dosed at 2200 and 0200 per the feeding tube</description>
        </group>
        <group group_id="B2">
          <title>Ramelteon First, Then Zolpidem</title>
          <description>dosed at 2200 and 0200 per the feeding tube</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.8" spread="1.6"/>
                <measurement group_id="B2" value="7.8" spread="1.6"/>
                <measurement group_id="B3" value="7.8" spread="1.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography Data</title>
        <description>Determine if intervention product elicits more total sleep time</description>
        <time_frame>2 weeks postburn</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Zolpidem</title>
            <description>medication dosed at 2200 and 0200 per feeding tube</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>dosed at 2200 and 0200 per the feeding tube</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Polysomnography Data</title>
            <description>Determine if intervention product elicits more total sleep time</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="373" spread="40"/>
                  <measurement group_id="O2" value="346" spread="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <description>evaluate the PK of zolpidem following standard dosing practices</description>
        <time_frame>2 weeks postburn</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zolpidem</title>
          <description>medication dosed at 2200 and 0200 per feeding tube
zolipidem: dosed at 2200 and 0200 per feeding tube</description>
        </group>
        <group group_id="E2">
          <title>Ramelteon</title>
          <description>dosed at 2200 and 0200 per the feeding tube
ramelteon: medication dosed at 2200 and 0200 per feeding tube</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michele Gottschlich PhD</name_or_title>
      <organization>Shriners Hospitals for Children</organization>
      <phone>513-872-6298</phone>
      <email>mgottschlich@shrinenet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
